Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers.

@article{Pourdehnad2013MycAM,
  title={Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers.},
  author={Michael Pourdehnad and Morgan L. Truitt and Imran N. Siddiqi and Gregory Stuart Ducker and Kevan M. Shokat and Davide Ruggero},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2013},
  volume={110 29},
  pages={
          11988-93
        }
}
Myc is one of the most commonly deregulated oncogenes in human cancer, yet therapies directly targeting Myc hyperactivation are not presently available in the clinic. The evolutionarily conserved function of Myc in modulating protein synthesis control is critical to the Myc oncogenic program. Indeed, enhancing the protein synthesis capacity of cancer cells directly contributes to their survival, proliferation, and genome instability. Therefore, inhibiting enhanced protein synthesis may… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 84 CITATIONS

FILTER CITATIONS BY YEAR

2013
2018

CITATION STATISTICS

  • 2 Highly Influenced Citations

  • Averaged 13 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 46 REFERENCES

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E

  • AC Hsieh
  • Cancer Cell 17(3):249–261
  • 2010
Highly Influential
6 Excerpts

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

  • NA Johnson
  • J Clin Oncol 30(28):3452–3459
  • 2012
3 Excerpts

MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by HDT/ASCT. A bio-CORAL report

  • CuccuiniW
  • Blood
  • 2012
1 Excerpt

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

  • Chng W-J
  • Leukemia
  • 2011
2 Excerpts

Similar Papers

Loading similar papers…